Sugi Predict

Sugi Predict / Compounds / SCHEMBL1360286

SCHEMBL1360286

SCHEMBL1360286

CCCc1nccn1-c1nc(-c2ccc(Cl)cc2)c(CCCOc2ccccc2OC)o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 1/20 0.37
▸ POLB P06746 2/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ MAPT P10636 3/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ CACNA1G O43497 2/20 0.33
▸ TSHR P16473 3/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ CYP2C9 P11712 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ DHPS P49366 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1361731 0.94 GCGR (0.37) GCGRPOLBSMN1; SMN2MAPTL3MBTL1
SCHEMBL1362811 0.94 GCGR (0.35) GCGRPOLBSMN1; SMN2MAPTL3MBTL1
SCHEMBL962882 0.88 MAPT (0.36) GCGRPOLBSMN1; SMN2MAPTL3MBTL1
SCHEMBL1360017 0.85 MAPT (0.36) GCGRPOLBSMN1; SMN2MAPTL3MBTL1
SCHEMBL1363270 0.85 TP53 (0.40) GCGRPOLBSMN1; SMN2MAPTMEN1
SCHEMBL1361746 0.84 GCGR (0.38) GCGRPOLBMAPTL3MBTL1CACNA1G
SCHEMBL1362205 0.83 GABRA2 (0.37) POLBMAPTTSHRMEN1KMT2A
SCHEMBL1361418 0.83 MAPT (0.42) GCGRPOLBSMN1; SMN2MAPTL3MBTL1
SCHEMBL1361404 0.81 L3MBTL1 (0.36) GCGRPOLBMAPTL3MBTL1TSHR
SCHEMBL1360319 0.81 TP53 (0.38) SMN1; SMN2MAPTMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 — — US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 — — US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 — — US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 — — EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 GCGR 470/4885POLB 4273/4885SMN1; SMN2 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.